SCHEMBL4664264

SCHEMBL4664264

O=CON(c1ccc(Nc2cc(-c3ccc(CN4CCOCC4)cc3)ncn2)cc1)S(=O)(=O)c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.41
JAK3 P52333 6/20 0.41
JAK1 P23458 5/20 0.41
ABL1 P00519 7/20 0.39
BCR P11274 7/20 0.39
ACP1 P24666 1/20 0.39
TP53 P04637 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
GLA P06280 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663887 0.93 ABL1 (0.41) JAK2JAK3JAK1ABL1BCR
SCHEMBL4663749 0.92 MEN1 (0.41) JAK2JAK3JAK1ABL1BCR
SCHEMBL4664341 0.92 ABL1 (0.41) JAK2JAK3JAK1ABL1BCR
SCHEMBL4665758 0.85 MEN1 (0.40) JAK2JAK3JAK1ABL1BCR
SCHEMBL4666183 0.84 ABL1 (0.42) JAK2JAK3JAK1ABL1BCR
SCHEMBL4664279 0.84 MEN1 (0.39) JAK2JAK3JAK1ABL1BCR
Formic Acid SCHEMBL4664261 0.83 JAK2 (0.46) JAK2JAK3JAK1ABL1BCR
SCHEMBL4665882 0.82 ABL1 (0.42) JAK2JAK3ABL1BCRTP53
SCHEMBL4667497 0.82 ABL1 (0.42) ABL1BCRTP53MEN1USP2
SCHEMBL4664335 0.81 ABL1 (0.43) ABL1BCRTP53MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 JAK2 63/4885JAK3 79/4885JAK1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.